Any 0 3 0 3 O
dermatological 4 18 4 18 B-chronic_disease
disorder 19 27 19 27 I-chronic_disease
that 28 32 28 32 O
may 33 36 33 36 O
interfere 37 46 37 46 O
with 47 51 47 51 O
the 52 55 52 55 O
accurate 56 64 56 64 O
evaluation 65 75 65 75 O
of 76 78 76 78 O
the 79 82 79 82 O
subject 83 90 83 90 O
's 90 92 90 92 O
skin 93 97 93 97 O

Aspirin 0 7 98 105 B-treatment

Clinically 0 10 106 116 O
significant 11 22 117 128 O
unstable 23 31 129 137 B-chronic_disease
medical 32 39 138 145 I-chronic_disease
disorders 40 49 146 155 I-chronic_disease

Female 0 6 156 162 B-gender
subjects 7 15 163 171 I-gender

History 0 7 172 179 O
of 8 10 180 182 O
, 10 11 182 183 O
diabetes 12 20 184 192 B-chronic_disease
, 20 21 192 193 O
heart 22 27 194 199 B-chronic_disease
or 28 30 200 202 I-chronic_disease
kidney 31 37 203 209 I-chronic_disease
disease 38 45 210 217 I-chronic_disease

Hydochlorothiazide 0 18 218 236 B-treatment

Immunosuppressant 0 17 237 254 B-treatment
's 17 19 254 256 I-treatment

Males 0 5 257 262 B-gender

Muscle 0 6 263 269 B-treatment
relaxants 7 16 270 279 I-treatment

must 0 4 280 284 O
be 5 7 285 287 O
between 8 15 288 295 O
the 16 19 296 299 O
ages 20 24 300 304 B-age
of 25 27 305 307 O
30 28 30 308 310 B-lower_bound
to 31 33 311 313 O
65 34 36 314 316 B-upper_bound
years 37 42 317 322 I-upper_bound
of 43 45 323 325 O
age 46 49 326 329 O

planning 0 8 330 338 B-pregnancy
a 9 10 339 340 I-pregnancy
pregnancy 11 20 341 350 I-pregnancy

starting 0 8 351 359 O
two 9 12 360 363 B-upper_bound
weeks 13 18 364 369 I-upper_bound
before 19 25 370 376 O
onset 26 31 377 382 O
of 32 34 383 385 O
study 35 40 386 391 O
and 41 44 392 395 O
also 45 49 396 400 O
during 50 56 401 407 O
the 57 60 408 411 O
study 61 66 412 417 O

